Načítá se...
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and...
Uloženo v:
| Vydáno v: | J Infect |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7195393/ https://ncbi.nlm.nih.gov/pubmed/32283143 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jinf.2020.03.060 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|